Precigen, Inc. (NASDAQ:PGEN – Get Rating) COO Rutul R. Shah bought 9,142 shares of Precigen stock in a transaction on Friday, January 27th. The shares were purchased at an average price of $1.75 per share, for a total transaction of $15,998.50. Following the acquisition, the chief operating officer now directly owns 62,037 shares in the company, valued at approximately $108,564.75. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Precigen Trading Down 4.9 %

Shares of PGEN opened at $1.56 on Tuesday. The business's fifty day simple moving average is $1.69 and its two-hundred day simple moving average is $1.92. Precigen, Inc. has a 12 month low of $1.12 and a 12 month high of $2.90. The company has a market cap of $324.71 million, a price-to-earnings ratio of 13.00 and a beta of 1.89.

Precigen (NASDAQ:PGEN – Get Rating) last issued its earnings results on Wednesday, November 9th. The biotechnology company reported ($0.04) EPS for the quarter, missing the consensus estimate of $0.10 by ($0.14). Precigen had a net margin of 33.55% and a negative return on equity of 82.23%. The business had revenue of $16.72 million for the quarter, compared to analysts' expectations of $51.72 million. As a group, research analysts forecast that Precigen, Inc. will post -0.41 EPS for the current year.

Wall Street Analysts Forecast Growth

Hedge Funds Weigh In On Precigen

Hedge funds and other institutional investors have recently modified their holdings of the company. Cresset Asset Management LLC bought a new position in shares of Precigen during the 1st quarter valued at $25,000. Sanford Advisory Services LLC bought a new position in shares of Precigen during the 3rd quarter valued at $32,000. The Manufacturers Life Insurance Company bought a new position in shares of Precigen during the 3rd quarter valued at $47,000. Inspire Investing LLC lifted its holdings in shares of Precigen by 57.5% during the 2nd quarter. Inspire Investing LLC now owns 26,170 shares of the biotechnology company's stock valued at $35,000 after buying an additional 9,554 shares during the period. Finally, Barclays PLC lifted its holdings in shares of Precigen by 416.4% during the 3rd quarter. Barclays PLC now owns 26,184 shares of the biotechnology company's stock valued at $55,000 after buying an additional 21,114 shares during the period.

About Precigen

(Get Rating)

Precigen, Inc is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the following segments: Biopharmaceuticals, Exemplar, and Trans Ova. The Biopharmaceuticals segment is involved in advancing the next generation of gene and cell therapies using precision technology to target urgent and intractable diseases in immuno-oncology, autoimmune disorders, and infectious diseases.

Further Reading

• Get a free copy of the StockNews.com research report on Precigen (PGEN)
• Why Gold Can Be A Glistening Addition To Your Portfolio Right Now
• SoFi Technologies Smashes Earnings but Beware the Fed Decision
• Buying The Dip In Colgate-Palmolive
• Mullen Automotive On Hiring Spree, What Could That Mean?
• InterDigital Raises Its Earnings Guidance

Receive News & Ratings for Precigen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precigen and related companies with MarketBeat.com's FREE daily email newsletter.